
Sunshine Biopharma Inc.
93
Recent developments highlight Sunshine Biopharma's expansion of its oncology support portfolio with generic Zofran and Ondansetron launches in Canada, multiple public offerings totaling $6 million, a reverse stock split with Canadian approval for Rivaroxaban, and quarterly revenue growth.
- Sunshine Biopharma expanded its oncology support portfolio by launching generic Zofran in Canada in September 2026 [N2].
- The company launched generic Ondansetron tablets in Canada in September 2026 [N3].
- Sunshine Biopharma priced a $6 million public offering in May 2026, closing on May 19 [N6].
- A subsequent $6 million public offering was priced in October 2026 [N1].
- Shares jumped 66% pre-market following a reverse stock split and Canadian approval for Rivaroxaban in June 2026 [N5].
- The company reported Q3 2024 revenue of $8.4 million, up from $5.96 million the prior year [N8].
Sunshine Biopharma Inc. operates as a pharmaceutical company with a focus on generic prescription drugs and proprietary drug development in oncology and antivirals. Its commercial operations are centered in Canada through Nora Pharma, which markets 71 generic drugs and holds 200 Drug Identification Numbers. The company expands its portfolio via in-licensing, cross-licensing, and distribution agreements. Proprietary drug development includes K1.1 mRNA for liver cancer and SBFM-PL4 targeting SARS Coronavirus protease inhibition, both in preclinical animal testing. Regulatory approvals are managed through Health Canada for generics and OTC supplements, with compliance to GMP standards. Financially, the company reported $9.44 million in revenue and a net loss of $1.22 million for Q3 2026, maintaining strong liquidity [S1][S2].
Sunshine Biopharma Inc. is a pharmaceutical company focused on oncology and antiviral medicines, operating primarily in Canada through its subsidiaries Nora Pharma and Sunshine Biopharma Canada. The company markets 71 generic prescription drugs in Canada and has a pipeline of 22 additional drugs, including proprietary mRNA and antiviral candidates in animal testing stages. Financial figures as of 2026-09-30 include quarterly revenue of $9.44 million USD and a net loss of $1.22 million USD, with strong liquidity ratios (current ratio 6.47, cash ratio 4.12). Recent developments include product launches in Canada, public offerings, and regulatory approvals [S1][S2][N1][N2][N3]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sunshine Biopharma's expanding generic drug portfolio and pipeline of 22 additional drugs, including 12 anticipated launches, enhance its market presence in Canada’s $10.4 billion generic drug market. Proprietary drug candidates in oncology and antivirals, supported by patent protections and promising preclinical results, offer potential for future product diversification. Recent successful public offerings and regulatory approvals demonstrate capital access and operational progress.
The company operates in a highly regulated environment with lengthy and uncertain approval processes, particularly for proprietary drugs requiring FDA approval. Financial losses and reliance on licensing and distribution agreements may limit control over product commercialization. Market competition in generics and potential regulatory changes pose risks to pricing and market share. Proprietary drug candidates remain in early development stages with inherent scientific and regulatory risks.
Sunshine Biopharma's moat derives from its extensive portfolio of generic drugs with established regulatory approvals in Canada, supported by 200 Drug Identification Numbers and strategic licensing agreements. Its proprietary drug development programs targeting oncology and coronavirus protease inhibition, backed by exclusive worldwide licenses and patent applications, provide potential differentiation. The company's manufacturing partnerships and regulatory compliance further support its market position in the Canadian pharmaceutical sector.
• Regulatory Approval Risks: Proprietary drugs require extensive FDA approval processes with no filings made yet, posing uncertainty on commercialization timelines and outcomes [S1].
• Market Competition and Pricing Pressure: The generic drug market in Canada is competitive with pricing influenced by the pan-Canadian Pharmaceutical Alliance, potentially limiting margins [S1].
• Financial Performance and Liquidity: The company reported a net loss of $1.22 million for Q3 2026 despite revenue growth, indicating ongoing profitability challenges [S2].
• Dependence on Licensing and Distribution Agreements: Sunshine Biopharma relies on third-party partners for manufacturing and distribution, which may affect supply chain control and costs [S1].
• Early Stage Proprietary Drug Development: Proprietary drug candidates are in animal testing stages, with inherent risks in clinical development and regulatory approval [S1].
Business trends: Expansion of generic drug portfolio in Canada with multiple product launches and ongoing proprietary drug development in oncology and antivirals.
Execution milestones: Completion of public offerings, regulatory approvals for new generics, and advancement of proprietary drug candidates through preclinical stages.
Key risks: Regulatory approval uncertainties for proprietary drugs, competitive pricing pressures in generics, and financial sustainability amid net losses.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Sunshine Biopharma Inc. is a pharmaceutical company focused on life-saving medicines in oncology and antivirals, with two wholly owned Canadian subsidiaries: Nora Pharma Inc. (marketing 71 generic prescription drugs in Canada) and Sunshine Biopharma Canada Inc. (developing and selling OTC supplements) [S1].
- The company procures rights to pharmaceutical products primarily for sale in Canada through in-licensing, cross-licensing, and distribution agreements, with products sold under Nora Pharma or partners' labels [S1].
- Nora Pharma holds 200 Drug Identification Numbers (DINs) for prescription drugs on the Canadian market, acquired via licensing or distribution agreements [S1].
- Sunshine Biopharma has 22 additional drugs in its pipeline, including 12 anticipated launches in 2026, covering cardiovascular, oncology, gastroenterology, CNS, diabetes, urology, endocrinology, anti-infective, and anti-inflammatory areas [S1].
- The company is developing proprietary drugs including K1.1 mRNA (an mRNA lipid nanoparticle for liver cancer) and SBFM-PL4 (a protease inhibitor targeting SARS Coronavirus infections), both in animal testing stages [S1].
- Sunshine Biopharma holds exclusive worldwide licenses for patents related to coronavirus protease inhibitors and filed provisional patents for mRNA molecules targeting cancer cells [S1].
- The company’s generic drugs are manufactured by international partners under long-term contracts, with approximately 75% of products sourced from India [S1].
- Regulatory approvals for generic drugs in Canada involve Health Canada’s Notice of Compliance (NOC) and Drug Identification Number (DIN), with pricing influenced by the pan-Canadian Pharmaceutical Alliance (pCPA) [S1].
- The company’s OTC supplements are regulated by the FDA and FTC in the U.S. and Health Canada in Canada, with compliance to Good Manufacturing Practices (GMP) [S1].
- Financial snapshot as of 2026-09-30 shows quarterly revenue of $9.44 million USD, net loss of $1.22 million USD, basic EPS of -$5.20, current assets of $31.0 million USD, current liabilities of $4.79 million USD, cash and equivalents of $19.7 million USD, current ratio of 6.47, and cash ratio of 4.12 [S2].
- Recent business developments include launching generic Ondansetron tablets and expanding oncology support portfolio with generic Zofran in Canada (September 2026) [N2][N3].
- The company priced a $6 million public offering in May 2026 and again in October 2026 [N6][N1].
- Sunshine Biopharma shares jumped 66% pre-market after a reverse stock split and Canadian approval for Rivaroxaban in June 2026 [N5].
- The company reported Q3 2024 revenue of $8.4 million USD, up from $5.96 million USD the prior year [N8].
Generated 2026-11-13
- S1 | 2026-04-03 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-10-08 | www.nasdaq.com | Sunshine Biopharma Prices $6 Million Public Offering; Stock Down | https://www.nasdaq.com/articles/sunshine-biopharma-prices-6-million-public-offering-stock-down
- N2 | 2026-09-24 | www.nasdaq.com | Sunshine Biopharma Expands Oncology Support Portfolio With Generic Zofran Launch In Canada | https://www.nasdaq.com/articles/sunshine-biopharma-expands-oncology-support-portfolio-generic-zofran-launch-canada
- N3 | 2026-09-24 | www.nasdaq.com | Sunshine Biopharma Launches Generic Ondansetron Tablets In Canada | https://www.nasdaq.com/articles/sunshine-biopharma-launches-generic-ondansetron-tablets-canada
- N4 | 2026-06-02 | www.nasdaq.com | Pre-Market Movers: BJDX, PMI, SBFM Drive Momentum | https://www.nasdaq.com/articles/pre-market-movers-bjdx-pmi-sbfm-drive-momentum
- N5 | 2026-06-02 | www.nasdaq.com | Sunshine Biopharma Shares Jump 66% Pre-Market After Reverse Split; Canadian OK For Rivaroxaban | https://www.nasdaq.com/articles/sunshine-biopharma-shares-jump-66-pre-market-after-reverse-split-canadian-ok-rivaroxaban
- N6 | 2026-05-19 | www.nasdaq.com | Sunshine Biopharma Prices $6M Offering; Closing May 19 | https://www.nasdaq.com/articles/sunshine-biopharma-prices-6m-offering-closing-may-19
- N7 | 2025-01-06 | www.nasdaq.com | Sunshine Biopharma files $100M mixed securities shelf | https://www.nasdaq.com/articles/sunshine-biopharma-files-100m-mixed-securities-shelf
- N8 | 2024-11-06 | www.nasdaq.com | Sunshine Biopharma reports Q3 revenue $8.4M vs. $5.96M last year | https://www.nasdaq.com/articles/sunshine-biopharma-reports-q3-revenue-84m-vs-596m-last-year
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


